12
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Rational design of peptides for identification of linear epitopes and generation of neutralizing monoclonal antibodies against DKK2 for cancer therapy

      research-article

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Dickkopf-related protein 2 (DKK2)is a member of the Dickkopf family in Wnt signaling pathway. Recently, we found that antibodies against DKK2 could activate natural killer (NK) and CD8+ T cells in tumors and inhibit tumor growth. In this paper, we report the rational design of peptides for identification of linear epitopes and generation of neutralizing monoclonal anti-DKK2 antibodies. To break the immune tolerance, we designed and chemically synthesized six peptides corresponding to different regions of DKK2 as immunogens and found five of them could generate mouse polyclonal antibodies that can bind to the active recombinant human DKK2 protein. Neutralizing mouse monoclonal antibodies (5F8 and 1A10) against human DKK2 were successfully developed by immunizing the mice with two different peptides ( 34KLNSIKSSL 42 and 240KVWKDATYS 248) conjugated to Keyhole limpet hemocyanin (KLH). The monoclonal antibodies not only abolish DKK2’s suppression of Wnt signaling in vitro but also inhibits tumor growth in vivo. Currently, those two mAbs are undergoing humanization as immunotherapy candidates and may offer a new drug for treatment of human cancers.

          Related collections

          Most cited references13

          • Record: found
          • Abstract: found
          • Article: not found

          The blockade of immune checkpoints in cancer immunotherapy.

          Among the most promising approaches to activating therapeutic antitumour immunity is the blockade of immune checkpoints. Immune checkpoints refer to a plethora of inhibitory pathways hardwired into the immune system that are crucial for maintaining self-tolerance and modulating the duration and amplitude of physiological immune responses in peripheral tissues in order to minimize collateral tissue damage. It is now clear that tumours co-opt certain immune-checkpoint pathways as a major mechanism of immune resistance, particularly against T cells that are specific for tumour antigens. Because many of the immune checkpoints are initiated by ligand-receptor interactions, they can be readily blocked by antibodies or modulated by recombinant forms of ligands or receptors. Cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) antibodies were the first of this class of immunotherapeutics to achieve US Food and Drug Administration (FDA) approval. Preliminary clinical findings with blockers of additional immune-checkpoint proteins, such as programmed cell death protein 1 (PD1), indicate broad and diverse opportunities to enhance antitumour immunity with the potential to produce durable clinical responses.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Function and biological roles of the Dickkopf family of Wnt modulators.

            C Niehrs (2006)
            Dickkopf (Dkk) genes comprise an evolutionary conserved small gene family of four members (Dkk1-4) and a unique Dkk3-related gene, Dkkl1 (soggy). They encode secreted proteins that typically antagonize Wnt/beta-catenin signaling, by inhibiting the Wnt coreceptors Lrp5 and 6. Additionally, Dkks are high affinity ligands for the transmembrane proteins Kremen1 and 2, which also modulate Wnt signaling. Dkks play an important role in vertebrate development, where they locally inhibit Wnt regulated processes such as antero-posterior axial patterning, limb development, somitogenesis and eye formation. In the adult, Dkks are implicated in bone formation and bone disease, cancer and Alzheimer's disease.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene.

              Germ-line mutations of the APC gene are responsible for familial adenomatous polyposis (FAP), an autosomal dominantly inherited disease in humans. Patients with FAP develop multiple benign colorectal tumors. Recently, a mouse lineage that exhibits an autosomal dominantly inherited predisposition to multiple intestinal neoplasia (Min) was described. Linkage analysis showed that the murine homolog of the APC gene (mApc) was tightly linked to the Min locus. Sequence comparison of mApc between normal and Min-affected mice identified a nonsense mutation, which cosegregated with the Min phenotype. This mutation is analogous to those found in FAP kindreds and in sporadic colorectal cancers.
                Bookmark

                Author and article information

                Contributors
                Journal
                Antib Ther
                Antib Ther
                anther
                Antibody Therapeutics
                Oxford University Press
                2516-4236
                April 2020
                13 April 2020
                13 April 2020
                : 3
                : 2
                : 63-70
                Affiliations
                [1 ] AbMax BioPharmaceuticals Co., LTD , Beijing 101111, China
                [2 ] Vascular Biology and Therapeutic Program and Department of Pharmacology, Yale School of Medicine , New Haven 201942, USA
                [3 ] AnyGo Technology Co., LTD , Beijing 100122, China
                [4 ] Hengyang Medical College, University of South China , Hengyang 421001, China
                Author notes
                To whom correspondence should be addressed. Le Sun, AbMax BioPharmaceuticals Co., LTD, 99 Kechuang 14th Street, BDA, Beijing, China; Email: sunl@ 123456antibodychina.com

                Rongqing Zhao and Qian Xiao contributed equally to this paper.

                Article
                tbaa004
                10.1093/abt/tbaa004
                7194219
                87658269-08b8-4235-ab32-597e1d214c22
                © The Author(s) 2020. Published by Oxford University Press on behalf of Antibody Therapeutics.

                This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

                History
                : 6 January 2020
                : 6 March 2020
                : 1 April 2020
                Page count
                Pages: 8
                Funding
                Funded by: Connecticut Bioscience Innovation Fund;
                Funded by: National Institutes of Health, DOI 10.13039/100000002;
                Award ID: CA214703
                Award ID: GM112182
                Funded by: Chinese Ministry of Science and Technology, DOI 10.13039/501100002855;
                Award ID: 2014 14C2621110037
                Categories
                Research Article

                dkk2,rational peptide design,neutralizing epitope,monoclonal antibody,immunotherapy

                Comments

                Comment on this article